

History of Changes for Study: NCT01012973

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Vein Occlusion (CRVO)

[Latest version \(submitted October 27, 2014\) on ClinicalTrials.gov](#)

- A study version is represented by a row in the table.
- Select two study versions to compare. One each from columns A and B.
- Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side comparison format applies to the Protocol section of the study.
- Click "Compare" to do the comparison and show the differences.
- Select a version's Submitted Date link to see a rendering of the study for that version.
- The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently selected.
- Hover over the "Recruitment Status" to see how the study's recruitment status changed.
- Study edits or deletions are displayed in **red**.
- Study additions are displayed in **green**.

Study Record Versions

Version	A	B	Submitted Date	Changes
1	<input checked="" type="radio"/>	<input checked="" type="radio"/>	November 12, 2009	None (earliest Version on record)
2	<input type="radio"/>	<input type="radio"/>	January 21, 2010	Contacts/Locations, Study Status, Study Identification and Study Description

<https://clinicaltrials.gov/ct2/history/NCT01012973?A=1&B=1&C=merged#StudyPageTop>

1/5/2021

History of Changes for Study: NCT01012973

Version	A	B	Submitted Date	Changes
3	<input type="radio"/>	<input type="radio"/>	February 9, 2010	Contacts/Locations and Study Status
4	<input type="radio"/>	<input type="radio"/>	March 16, 2010	Contacts/Locations, Study Status and Study Identification
5	<input type="radio"/>	<input type="radio"/>	April 16, 2010	Contacts/Locations, Study Status and Study Identification
6	<input type="radio"/>	<input type="radio"/>	July 22, 2010	Contacts/Locations, Study Status, Eligibility and Arms and Interventions
7	<input type="radio"/>	<input type="radio"/>	August 25, 2010	Study Status and Contacts/Locations
8	<input type="radio"/>	<input type="radio"/>	August 26, 2010	Recruitment Status, Study Status and Contacts/Locations
9	<input type="radio"/>	<input type="radio"/>	September 8, 2010	Study Status
10	<input type="radio"/>	<input type="radio"/>	October 4, 2010	Study Status
11	<input type="radio"/>	<input type="radio"/>	November 1, 2010	Study Status
12	<input type="radio"/>	<input type="radio"/>	January 25, 2011	Study Status and Contacts/Locations
13	<input type="radio"/>	<input type="radio"/>	April 8, 2011	Study Status and Study Design
14	<input type="radio"/>	<input type="radio"/>	June 23, 2011	Arms and Interventions, Study Status, Contacts/Locations and Eligibility
15	<input type="radio"/>	<input type="radio"/>	September 19, 2011	Study Status
16	<input type="radio"/>	<input type="radio"/>	November 29, 2011	Study Status and Study Identification
17	<input type="radio"/>	<input type="radio"/>	January 26, 2012	Study Status and Contacts/Locations
18	<input type="radio"/>	<input type="radio"/>	February 20, 2012	Recruitment Status and Study Status
19	<input type="radio"/>	<input type="radio"/>	October 23, 2012	Outcome Measures, Arms and Interventions, Study Status, More Information, Reported Adverse Events, Baseline Characteristics and Participant Flow
20	<input type="radio"/>	<input type="radio"/>	December 18, 2012	Arms and Interventions, Study Status and Baseline Characteristics

<https://clinicaltrials.gov/ct2/history/NCT01012973?A=1&B=1&C=merged#StudyPageTop>

1/5/2021

History of Changes for Study: NCT01012973

Version	A	B	Submitted Date	Changes
21	<input type="radio"/>	<input type="radio"/>	January 18, 2013	Arms and Interventions, Study Status and Baseline Characteristics
22	<input type="radio"/>	<input type="radio"/>	January 30, 2014	Contacts/Locations, Sponsor/Collaborators, Study Status, Baseline Characteristics and F
23	<input type="radio"/>	<input type="radio"/>	October 27, 2014	Study Status and References

Compare

Comparison Format: Merged
 Side-by-Side

[Scroll up to access the controls](#)

Study NCT01012973

Submitted Date: November 12, 2009 (v1)

Study Identification

Unique Protocol ID: 14130

Brief Title: Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Retinal Vein Occlusion (CRVO)

Official Title: A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Secondary IDs: EudraCT: 2009-010973-19
GALILEO

Study Status

Record Verification: November 2009

Overall Status: Recruiting

Study Start: October 2009

<https://clinicaltrials.gov/ct2/history/NCT01012973?A=1&B=1&C=merged#StudyPageTop>

Primary Completion: February 2011 [Anticipated]

Study Completion: August 2012 [Anticipated]

First Submitted: October 30, 2009

First Submitted that Met QC Criteria: November 12, 2009

Met QC Criteria:

First Posted: November 13, 2009 [Estimate]

Last Update Submitted that Met QC Criteria: November 12, 2009

Met QC Criteria:

Last Update Posted: November 13, 2009 [Estimate]

Sponsor/Collaborators

Sponsor: Bayer

Responsible Party:

Collaborators: Regeneron Pharmaceuticals

Oversight

U.S. FDA-regulated Drug:

U.S. FDA-regulated Device:

Data Monitoring: Yes

Study Description

Brief Summary: To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injection on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.

Detailed Description:

Conditions

Conditions: Retinal Vein Occlusion

Keywords: Macular Edema

Central Retinal Vein Occlusion

CRVO
 VEGF Trap-Eye
 best-corrected visual acuity

Study Design

Study Type: Interventional
 Primary Purpose: Treatment
 Study Phase: Phase 3
 Interventional Study Model: Parallel Assignment
 Number of Arms: 2
 Masking: Triple (Participant, Investigator, Outcomes Assessor)
 Allocation: Randomized
 Enrollment: 165 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions
Experimental: Arm 1	Drug: VEGF Trap-Eye (BAY86-5321) Intravitreal injection. Weeks 0 to 20 injecti Eye every 4 weeks; weeks 24 to 48 every assessment and either (PRN) injection of sham injection; weeks 52 to 100 safety fo
Sham Comparator: Arm 2	Sham treatment Sham treatment. Weeks 0 to 20 sham trea weeks; weeks 24 to 48 every 4 weeks re- sham injection; weeks 52 to 100 safety fo

Outcome Measures

Primary Outcome Measures:

1. The proportion of subjects who gain at least 15 letters in BCVA on the EDTRS chart compared with baseline

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.